CAMBRIDGE, Mass. – ONO PHARMA USA announced today partnerships with LabCentral in Cambridge, Mass., and MBC BioLabs in San Francisco and San Carlos, CA, which both are offering One Golden Ticket to early-stage life science organizations.
The competition is sponsored by ONO PHARMA USA‘s parent company, Ono Pharmaceutical Co., Ltd. (Ono), and applications will be received through May 2025.
That means two are promising early-stage and will allow lab space through components, while vitalize the startup businesses.
The Golden Ticket competition is geared towards companies focused on oncology, immunology, neurology, and specialty areas.
Winners will receive not only lab space at either LabCentral or MBC BioLabs, but also mentorship from Ono’s researchers and business leaders. This support is designed to help these young companies navigate the challenging early stages of research and development, giving them a leg up in a competitive industry.
Interested startups in Cambridge, San Francisco, and San Carlos can submit their proposals to LabCentral by May 30th, and to MBC BioLabs by June 6th.
Finalists will be invited to present their work to Ono in July, with winners announced shortly thereafter.
This competition provides a valuable opportunity for emerging biotech companies to gain access to state-of-the-art facilities and invaluable mentorship from industry leaders.
This initiative underscores the growing importance of collaboration between established pharmaceutical companies and innovative startups. By fostering these partnerships, Ono aims to tap into cutting-edge research and accelerate the delivery of new therapies to patients worldwide.
Kunihiko Ito, President and CEO of ONO PHARMA USA stated his excitement to be partnering with LabCentral and MBC Labs.
As longtime believers in open innovation and the power of partnerships, we are excited to be partnering with LabCentral and MBC BioLabs to offer this Golden Ticket competition,We encourage companies who are doing outstanding work in Ono’s four focus areas – oncology, immunology, neurology, and specialty medicine – to apply. It’s our goal to deliver first-in-class medicines to patients who are waiting for them, by leveraging startup technology and Ono’s expertise
Kunihiko Ito, President and CEO of ONO PHARMA USA
ONO PHARMA USA is committed to partnering to promote the advancement of health. Their approach has helped them drive success. Their mission is dedicated to new drug candidates.
If you click on a link and make a purchase we may receive a small commission. Learn more. All content on this site is provided with no warranties, express or implied. Use any information at your own risk. Privacy Policy.
Discover more from BITVoxy
Subscribe to get the latest posts sent to your email.
)